Antibodies that bind complement components were first identified over 30 years ago. Investigations into their functions in animal models motivated clinical studies that have now generated licensed products and a strong pipeline of future therapeutics. Despite this, the mechanisms of action of one of the first effective C5‐binding antibodies, BB5.1, were not known. Here, we report a new study that reveals these mechanisms, enabling new approaches for designing C5‐binding molecules for therapeutic use.

中文翻译：

---

从原型补体 C5 抗体 BB5.1 的功能到机制

30 多年前首次发现了结合补体成分的抗体。对它们在动物模型中的功能的研究激发了临床研究，这些研究现在已经产生了许可产品和强大的未来疗法。尽管如此，第一个有效的 C5 结合抗体 BB5.1 的作用机制尚不清楚。在这里，我们报告了一项揭示这些机制的新研究，为设计用于治疗用途的 C5 结合分子提供了新的方法。